Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis

BACKGROUND: Little data exist on the use of direct oral anticoagulant (DOAC) factor Xa inhibitors for submassive pulmonary embolism (PE) after catheter-directed thrombolysis (CDT). The objective of this evaluation was to determine whether the transition from parenteral anticoagulation to DOACs for s...

Descripción completa

Detalles Bibliográficos
Autores principales: Groetzinger, Lara M., Miller, Taylor J., Rivosecchi, Ryan M., Smith, Roy E., Gladwin, Mark T., Rivera-Lebron, Belinda N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714714/
https://www.ncbi.nlm.nih.gov/pubmed/29455567
http://dx.doi.org/10.1177/1076029618755311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714714/
https://www.ncbi.nlm.nih.gov/pubmed/29455567
http://dx.doi.org/10.1177/1076029618755311

Ejemplares similares